{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:37:11Z","timestamp":1776130631430,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:00:00Z","timestamp":1658102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006538","name":"School of Medicine, Vanderbilt University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006538","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s40257-022-00709-9","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T07:02:39Z","timestamp":1658127759000},"page":"739-746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Suggestions for a New Clinical Classification Approach to Panniculitis Based on a Mayo Clinic Experience of 207 Cases"],"prefix":"10.1007","volume":"23","author":[{"given":"Nimay C.","family":"Anand","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Takaichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma F.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A.","family":"Wetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D. P.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1171-4917","authenticated-orcid":false,"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,18]]},"reference":[{"issue":"4","key":"709_CR1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1111\/ijd.15224","volume":"60","author":"E Shavit","year":"2021","unstructured":"Shavit E, Marzano AV, Alavi A. Ulcerative versus non-ulcerative panniculitis: is it time for a novel clinical approach to panniculitis? Int J Dermatol. 2021;60(4):407\u201317.","journal-title":"Int J Dermatol"},{"issue":"11","key":"709_CR2","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.revmed.2016.05.008","volume":"37","author":"C Velter","year":"2016","unstructured":"Velter C, Lipsker D. Cutaneous panniculitis [in French]. Rev Med Interne. 2016;37(11):743\u201350.","journal-title":"Rev Med Interne"},{"issue":"3","key":"709_CR3","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/archdermatol.2009.21","volume":"145","author":"O Durosaro","year":"2009","unstructured":"Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965\u20132005: a population-based study. Arch Dermatol. 2009;145(3):249\u201353.","journal-title":"Arch Dermatol"},{"issue":"4","key":"709_CR4","doi-asserted-by":"publisher","first-page":"22376","DOI":"10.5070\/D3204022376","volume":"20","author":"T Blake","year":"2014","unstructured":"Blake T, Manahan M, Rodins K. Erythema nodosum: a review of an uncommon panniculitis. Dermatol Online J. 2014;20(4):22376.","journal-title":"Dermatol Online J"},{"issue":"3","key":"709_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1053\/j.semdp.2016.12.004","volume":"34","author":"MR Wick","year":"2017","unstructured":"Wick MR. Panniculitis: a summary. Semin Diagn Pathol. 2017;34(3):261\u201372.","journal-title":"Semin Diagn Pathol"},{"issue":"4","key":"709_CR6","first-page":"325","volume":"148","author":"G Borroni","year":"2013","unstructured":"Borroni G, Giorgini C, Tomasini C, Brazzelli V. How to make a specific diagnosis of panniculitis on clinical grounds alone: an integrated pathway of general criteria and specific findings. G Ital Dermatol Venereol. 2013;148(4):325\u201333.","journal-title":"G Ital Dermatol Venereol"},{"issue":"2","key":"709_CR7","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.sder.2007.02.001","volume":"26","author":"L Requena","year":"2007","unstructured":"Requena L. Normal subcutaneous fat, necrosis of adipocytes and classification of the panniculitides. Semin Cutan Med Surg. 2007;26(2):66\u201370.","journal-title":"Semin Cutan Med Surg"},{"key":"709_CR8","volume-title":"Panniculitis","author":"L Requena","year":"2008","unstructured":"Requena L. Panniculitis. Philadelphia: Saunders; 2008."},{"issue":"4","key":"709_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/j.1529-8019.2010.01333.x","volume":"23","author":"LK Morrison","year":"2010","unstructured":"Morrison LK, Rapini R, Willison CB, Tyring S. Infection and panniculitis. Dermatol Ther. 2010;23(4):328\u201340.","journal-title":"Dermatol Ther"},{"issue":"6","key":"709_CR10","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1007\/s12519-018-0191-1","volume":"14","author":"AKC Leung","year":"2018","unstructured":"Leung AKC, Leong KF, Lam JM. Erythema nodosum. World J Pediatr. 2018;14(6):548\u201354.","journal-title":"World J Pediatr."},{"issue":"2","key":"709_CR11","first-page":"216","volume":"153","author":"R Filotico","year":"2018","unstructured":"Filotico R, Mastrandrea V. Cutaneous lupus erythematosus: clinico-pathologic correlation. G Ital Dermatol Venereol. 2018;153(2):216\u201329.","journal-title":"G Ital Dermatol Venereol"},{"issue":"4","key":"709_CR12","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.det.2008.06.002","volume":"26","author":"J Fraga","year":"2008","unstructured":"Fraga J, Garcia-Diez A. Lupus erythematosus panniculitis. Dermatol Clin. 2008;26(4):453\u201363.","journal-title":"Dermatol Clin"},{"issue":"4","key":"709_CR13","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1529-8019.2010.01334.x","volume":"23","author":"CB Hansen","year":"2010","unstructured":"Hansen CB, Callen JP. Connective tissue panniculitis: lupus panniculitis, dermatomyositis, morphea\/scleroderma. Dermatol Ther. 2010;23(4):341\u20139.","journal-title":"Dermatol Ther"},{"key":"709_CR14","unstructured":"Herrerin CL, et al. El lupus paniculitis: una paniculitis mixta. 1987."},{"issue":"1","key":"709_CR15","first-page":"68","volume":"26","author":"PB Martens","year":"1999","unstructured":"Martens PB, Moder KG, Ahmed I. Lupus panniculitis: clinical perspectives from a case series. J Rheumatol. 1999;26(1):68\u201372.","journal-title":"J Rheumatol"},{"key":"709_CR16","doi-asserted-by":"crossref","unstructured":"Requena L, Sanchez Yus E. Panniculitis. Part II. Mostly lobular panniculitis. J Am Acad Dermatol. 2001;45(3):325\u201361.","DOI":"10.1067\/mjd.2001.114735"},{"issue":"5","key":"709_CR17","first-page":"298","volume":"100","author":"S Bonkemeyer Millan","year":"2019","unstructured":"Bonkemeyer Millan S, Gan R, Townsend PE. Venous ulcers: diagnosis and treatment. Am Fam Physician. 2019;100(5):298\u2013305.","journal-title":"Am Fam Physician"},{"issue":"4","key":"709_CR18","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.jaad.2014.10.048","volume":"74","author":"A Alavi","year":"2016","unstructured":"Alavi A, Sibbald RG, Phillips TJ, Miller OF, Margolis DJ, Marston W, et al. What\u2019s new: management of venous leg ulcers: approach to venous leg ulcers. J Am Acad Dermatol. 2016;74(4):627\u201340.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"709_CR19","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1529-8019.2010.01338.x","volume":"23","author":"M Miteva","year":"2010","unstructured":"Miteva M, Romanelli P, Kirsner RS. Lipodermatosclerosis. Dermatol Ther. 2010;23(4):375\u201388.","journal-title":"Dermatol Ther"},{"issue":"10","key":"709_CR20","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.5858\/arpa.2014-0270-CC","volume":"138","author":"MP Chan","year":"2014","unstructured":"Chan MP. Neutrophilic panniculitis: algorithmic approach to a heterogeneous group of disorders. Arch Pathol Lab Med. 2014;138(10):1337\u201343.","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"709_CR21","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1097\/DAD.0000000000001597","volume":"42","author":"M Llamas-Velasco","year":"2020","unstructured":"Llamas-Velasco M, Fraga J, Sanchez-Schmidt JM, Fernandez-Figueras M, Gallardo F, Rutten A, et al. Neutrophilic infiltrates in panniculitis: comprehensive review and diagnostic algorithm proposal. Am J Dermatopathol. 2020;42(10):717\u201330.","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"709_CR22","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1309\/TYRGT196N2APLLR9","volume":"121","author":"M Takeshita","year":"2004","unstructured":"Takeshita M, Imayama S, Oshiro Y, Kurihara K, Okamoto S, Matsuki Y, et al. Clinicopathologic analysis of 22 cases of subcutaneous panniculitis-like CD56- or CD56+ lymphoma and review of 44 other reported cases. Am J Clin Pathol. 2004;121(3):408\u201316.","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"709_CR23","first-page":"606","volume":"86","author":"KD Baxi","year":"2020","unstructured":"Baxi KD, Rathod SP, Chaudhary RG, Jagati A. Subcutaneous panniculitis-like T-cell lymphoma. Indian J Dermatol Venereol Leprol. 2020;86(5):606.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"2","key":"709_CR24","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","volume":"111","author":"R Willemze","year":"2008","unstructured":"Willemze R, Jansen PM, Cerroni L, Berti E, Santucci M, Assaf C, et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008;111(2):838\u201345.","journal-title":"Blood"},{"issue":"1","key":"709_CR25","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1046\/j.1523-1755.2001.00803.x","volume":"60","author":"AR Mazhar","year":"2001","unstructured":"Mazhar AR, Johnson RJ, Gillen D, Stivelman JC, Ryan MJ, Davis CL, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60(1):324\u201332.","journal-title":"Kidney Int"},{"issue":"6","key":"709_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1097\/DAD.0000000000000023","volume":"36","author":"B Choy","year":"2014","unstructured":"Choy B, Chou S, Anforth R, Fernandez-Penas P. Panniculitis in patients treated with BRAF inhibitors: a case series. Am J Dermatopathol. 2014;36(6):493\u20137.","journal-title":"Am J Dermatopathol"},{"issue":"7","key":"709_CR27","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1097\/DAD.0000000000000528","volume":"38","author":"I Vazquez-Osorio","year":"2016","unstructured":"Vazquez-Osorio I, Sanchez-Aguilar MD, Garcia-Rodino S, Suarez-Penaranda JM, Aliste C, Vazquez-Veiga H. Vemurafenib-induced neutrophilic panniculitis: a new case and review of the literature. Am J Dermatopathol. 2016;38(7):e93\u20136.","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"709_CR28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/pde.13148","volume":"34","author":"N Finelt","year":"2017","unstructured":"Finelt N, Lulla RR, Melin-Aldana H, Ruth JS, Lin FY, Su JM, et al. Bumps in the road: panniculitis in children and adolescents treated with vemurafenib. Pediatr Dermatol. 2017;34(3):337\u201341.","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"709_CR29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jaad.2014.07.033","volume":"72","author":"JB Macdonald","year":"2015","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies: part II: inhibitors of intracellular molecular signaling pathways. J Am Acad Dermatol. 2015;72(2):221\u201336.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"709_CR30","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.annder.2020.07.013","volume":"147","author":"M Piroth","year":"2020","unstructured":"Piroth M, Frenard C, Eugene-Lamer J, Dreno B, Quereux G. Panniculitis during BRAF inhibitor and\/or MEK inhibitor therapy: a new case report and literature review [in French]. Ann Dermatol Venereol. 2020;147(12):833\u201341.","journal-title":"Ann Dermatol Venereol"},{"issue":"1","key":"709_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/pbc.20194","volume":"44","author":"E Kismet","year":"2005","unstructured":"Kismet E, Demirkaya E, Koseoglu V, Deveci S, Atay AA. Panniculitis induced by a chemotherapy regimen consisting of topotecan and cyclophosphamide. Pediatr Blood Cancer. 2005;44(1):98\u20139.","journal-title":"Pediatr Blood Cancer"},{"key":"709_CR32","first-page":"4","volume":"2020","author":"A Mohamednour","year":"2020","unstructured":"Mohamednour A, Khan S, Sunmboye K, Kinder A. A rare case of anti-TNF induced panniculitis. Rheumatol Adv Pract. 2020;2020:4.","journal-title":"Rheumatol Adv Pract."},{"issue":"5","key":"709_CR33","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.3390\/jcm10051040","volume":"10","author":"JLW Lambert","year":"2021","unstructured":"Lambert JLW, De Schepper S, Speeckaert R. Cutaneous manifestations in biological-treated inflammatory bowel disease patients: a narrative review. J Clin Med. 2021;10(5):1040.","journal-title":"J Clin Med"},{"issue":"6","key":"709_CR34","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.survophthal.2010.05.001","volume":"55","author":"I Mavrikakis","year":"2010","unstructured":"Mavrikakis I, Georgiadis T, Fragiadaki K, Sfikakis PP. Orbital lobular panniculitis in Weber-Christian disease: sustained response to anti-TNF treatment and review of the literature. Surv Ophthalmol. 2010;55(6):584\u20139.","journal-title":"Surv Ophthalmol"},{"key":"709_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100357","volume":"27","author":"D Antwi-Amoabeng","year":"2021","unstructured":"Antwi-Amoabeng D, Ghuman J, Ghuman J, Beutler BD, Ulanja MB, Kuriakose K, et al. Ponatinib-associated panniculitis: case report and review of the literature. Cancer Treat Res Commun. 2021;27: 100357.","journal-title":"Cancer Treat Res Commun."},{"issue":"6","key":"709_CR36","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s40257-020-00535-x","volume":"21","author":"V Sibaud","year":"2020","unstructured":"Sibaud V, Beylot-Barry M, Protin C, Vigarios E, Recher C, Ysebaert L. Dermatological toxicities of Bruton\u2019s tyrosine kinase inhibitors. Am J Clin Dermatol. 2020;21(6):799\u2013812.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"709_CR37","first-page":"263","volume":"149","author":"G Borroni","year":"2014","unstructured":"Borroni G, Torti S, D\u2019Ospina RM, Pezzini C. Drug-induced panniculitides. G Ital Dermatol Venereol. 2014;149(2):263\u201370.","journal-title":"G Ital Dermatol Venereol"},{"issue":"5","key":"709_CR38","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1001\/jamaoncol.2015.0457","volume":"1","author":"SK Fabbro","year":"2015","unstructured":"Fabbro SK, Smith SM, Dubovsky JA, Gru AA, Jones JA. Panniculitis in patients undergoing treatment with the Bruton tyrosine kinase inhibitor ibrutinib for lymphoid leukemias. JAMA Oncol. 2015;1(5):684\u20136.","journal-title":"JAMA Oncol"},{"issue":"2","key":"709_CR39","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1097\/DAD.0000000000000980","volume":"40","author":"J Stewart","year":"2018","unstructured":"Stewart J, Bayers S, Vandergriff T. Self-limiting ibrutinib-induced neutrophilic panniculitis. Am J Dermatopathol. 2018;40(2):e28\u20139.","journal-title":"Am J Dermatopathol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00709-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-022-00709-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-022-00709-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T02:19:14Z","timestamp":1662949154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-022-00709-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,18]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["709"],"URL":"https:\/\/doi.org\/10.1007\/s40257-022-00709-9","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,18]]},"assertion":[{"value":"8 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Nimay Anand is funded by the Vanderbilt Medical Scholars Program. No other funding sources were used to assist in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Afsaneh Alavi is an investigator for Boehringer Ingelheim and Processa Pharmaceuticals, and a consultant for AbbVie, Boehringer Ingelheim, InflaRx, Novartis, and UCB. Nimay C. Anand, Mika Takaichi, Emma F. Johnson, David A. Wetter, and Mark D.P. Davis have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All data generated and\/or analyzed during this study are included in this published article (and its supplementary information files).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"This retrospective chart review study involving human participants was in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This study was approved by the Mayo Clinic Institutional Review Board (#20-010125).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The Mayo Clinic Institutional Review Board approved the study and waived written informed consent for those who provided research authorization.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Concept and design: EFJ, DAW, AA. Acquisition, analysis, or interpretation of data: NCA, EFJ, AA. Drafting of the manuscript: NCA, AA. Critical revision of the manuscript: All authors.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}